JNK-mediated microglial DICER degradation potentiates inflammatory responses to induce dopaminergic neuron loss

Qing Wang†, Qian He†, Yifei Chen†, Wei Shao†, Chao Yuan† and Yizheng Wang*†

Abstract

Background: Amplified inflammation is important for the progression of Parkinson's disease (PD). However, how this enhanced inflammation is regulated remains largely unknown. Deletion of DICER leads to progressive dopamine neuronal loss and induces gliosis. We hypothesized that the homeostasis of microglial DICER would be responsible for the amplified inflammation in the mouse model of PD.

Methods: The microglia or C57BL/6 mice were treated or injected with l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium (MPP+), respectively, for the model establishment. Microglia and astrocytes sorted by fluorescence-activated cell sorter (FACS) were assayed by quantitative real-time PCR, Western blotting, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), immunohistofluorescence, and mass spectrometry.

Results: Microglial DICER was phosphorylated at serine 1456 by c-jun N-terminal kinase (JNK) and downregulated in response to 1-methyl-4-phenylpyridinium (MPP+), a causative agent in PD. Inhibition of JNK phosphorylation of DICER at serine 1456 rescued the MPP+-induced DICER degradation, suppressed microglial inflammatory process, and prevented the loss of tyrosine hydroxylase-expressing neurons in the mouse MPTP model.

Conclusions: JNK-mediated microglial DICER degradation potentiates inflammation to induce dopaminergic neuronal loss. Thus, preventing microglial DICER degradation could be a novel strategy for controlling neuroinflammation in PD.

Keywords: DICER, Microglia, Inflammation, Degradation, Phosphorylation

Background

Parkinson's disease (PD) is the second prevalent neurodegenerative disease worldwide and is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) [1]. Studies have shown that the development and progression of PD are accompanied by the microglial inflammatory process [2]. Activated microglia and elevated pro-inflammatory factors, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β), have been found in the brains of PD patients and various PD models [3–5]. Lipopolysaccharide (LPS), a bacterial endotoxin, can activate microglial inflammatory responses to induce degeneration of nigrostriatal dopamine neurons [6]. Anti-inflammatory agents, including naloxone and dexamethasone, can inhibit the activation of microglia and the production of pro-inflammatory cytokines to protect nigral dopaminergic neurons from degeneration [7, 8]. These observations suggest that manipulation of microglial inflammatory responses can alter disease progression. Therefore, exploration of the regulatory mechanism underlying the microglial inflammatory responses will provide important information to PD pathogenesis and treatment.

The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) metabolite MPP+ is the causative agent in MPTP-induced parkinsonism in man and animals [9, 10]. MPTP can produce Parkinsonian-like syndrome in animal models [11]. Astrocytes convert MPTP into 1-methyl-4-phenylpyridinium (MPP+) which is uptaken by neurons to cause oxidative stress, and neuronal death and debris released from damaged neurons activate microglia to promote inflammation, leading to more neuronal loss [12]. Therefore, activated microglia...
has a crucial role in propagating this vicious cycle of neuronal damage. A recent work shows that MPP+ can potentiate TNF-α production in microglia by downregulating miR-7116-5p, a microRNA targeting TNF-α [9]. The important roles of microglial micro-RNAs in regulating inflammatory responses are also shown in various kinds of diseases, including experimental autoimmune encephalomyelitis, intracerebral hemorrhage, and amyotrophic lateral sclerosis [13–15]. These studies suggest that dysregulated micro-RNAs contribute to microglial inflammatory responses. As DICER, an RNase III family enzyme, is required for processing pre-miRNAs into mature microRNAs, exploring its potential involvement in microglial inflammatory responses might reveal novel insight into the molecular mechanism of inflammation in the PD brain.

Previous studies also show that artificial deletion of DICER in postmitotic dopamine neurons leads to progressive neuronal loss and that mice with DICER deletion in striatal neurons display ataxia, front and hind limb clasp ing, reduced brain size, and smaller neurons [16]. The DICER ablation in oligodendrocytes triggers gliosis and increases expression of inflammation markers [17]. The DICER deficit activates the NLRP3 inflammasome in the retinal pigmented epithelium [18]. However, whether DICER directly modulates microglial inflammatory responses in the MPTP model of PD remains unknown. In the current study, we report that MPP+ induces c-jun N-terminal kinase (JNK)-dependent and proteasome-mediated microglial DICER degradation to potentiate microglial inflammatory response and dopamine neuron loss. Our findings reveal a novel mechanism by which microglial inflammatory responses are controlled and potentiated in the PD models.

Methods

Animals

The C57BL/6 mice were from SLAK Laboratory Animal Shanghai, China. For the MPTP model, male wild-type C57BL/6 mice (8–10 weeks, n = 6 for each indicated group) were intraperitoneally injected with saline or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at 20 mg/kg for four times with 2 h intervals in 1 day as reported previously [19]. The successful establishment of the model was confirmed as about 60% loss of dopaminergic (DA) neurons in SNpc [12]. For the peptide blocking experiments, the fusion peptides at 250 mg/kg TAT-scramble or TAT-DICER (by China Peptides) were co-injected with MPTP or saline into the mice. The mice were sacrificed for Western blotting analysis or immunohistofluorescence, 3 or 7 days, respectively, after MPTP or saline injection.

Microglia and astrocytes sorting from adult mouse ventral midbrain

The ventral midbrain isolated from the brain of mice anesthetized was filtered through a 70-μm nylon cell strainer and digested with collagenase D (0.05%, Sigma, C5138) and DNase I (0.025 U/ml, Sigma) for 1 h at room temperature as reported previously [9]. After three washes with Hank’s Balanced Salt Solution (HBSS, Invitrogen) to remove the enzymes, cells were resuspended and then stained with allophycocyanin (APC)-labeled cluster of differentiation 45 (CD45)/Alexa Fluor 488-labeled crossing cluster of differentiation molecule 11B (CD11b), APC-labeled glutamate aspartate transporter (GLAST) antibodies, or Alexa Fluor 488/APC-labeled isotype at 4 °C for 1 h. CD11b+ /CD45low or GLAST- populations were then sorted by the flow cytometry (Cell Lab Quanta SC; Beckman Coulter, CA).

Cell cultures, transfection, and drug treatment

The microglia and astrocytes were obtained from the cerebral cortices of C57BL/6 mouse pups postnatal day 0–1 as reported previously [9]. Briefly, the mouse cerebral cortices were isolated in cold phosphate-buffered saline (PBS), a water-based salt solution maintaining a constant pH, osmolarity, and ion concentrations and then digested for 6 min at 37 °C in 0.25% trypsin followed by adding culture medium to terminate digestion. After filtered through the 70 μm cell strainer, the suspensions were centrifuged at 1000 rpm for 3 min, and the pellets were then resuspended in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and antibiotics. Finally, the cells were cultured on 75 cm² flasks. Seven to 9 days after seeding, the cells were then stained with allophycocyanin (APC)-labeled cluster of differentiation 45 (CD45)/Alexa Fluor 488-labeled crossing cluster of differentiation molecule 11B (CD11b), APC-labeled glutamate aspartate transporter (GLAST) antibodies, or Alexa Fluor 488/APC-labeled isotype at 4 °C for 1 h. CD11b+/CD45low or GLAST- populations were then sorted by the flow cytometry (Cell Lab Quanta SC; Beckman Coulter, CA).

RNA isolation and quantitative real-time PCR

The total RNA was extracted from microglia or BV2 cells using the Trizol reagent according to the manufacturer’s
instructions. A total of 1 or 5 μg RNA from microglia or BV2 cells, respectively, were reverse-transcribed into cDNA using a reverse transcription system followed by quantitative real-time PCR (qRT-PCR) analysis. Target mRNA expression was quantified using the comparative Ct method (ΔΔCt method) and normalized to the reference gene level expression. The PCR primer sequences for mRNA analysis were as follows:

DICER: forward 5′-GGTCCTTTTGGGACTGCCA-3′, reverse 5′-GGATGGCTTTCCCTGA-3′.

TNF-α: forward 5′-CTATGGCCAGACCTCACA-3′, reverse 5′-TGAGATCCATGCGTGG-3′.

IL-1β: forward 5′-GCAACTGTTCCTGAACTCAAC-3′, reverse 5′-ATCTTTTGGGTCGTCAC-3′.

COX-2: forward 5′-TGAGCAAACATTCACCCCGATC-3′, reverse 5′-GCACGTAGTCTTCGATCACTATC-3′.

iNOS: forward 5′-GTTCCTAGCCAACAAATCACA-3′, reverse 5′-GGAGACGGGTGCATGTACAC-3′.

Actin: forward 5′-GGCTGTATTCCCCTCCATAC-3′, reverse 5′-CCAGTTGGTAACAAATGCATGG-3′.

The identities of the PCR products were confirmed by sequencing analysis.

### MTT assay

Microglia and BV2 cells were seeded on 12-well plates, and the medium was replaced with fresh DMEM or DMEM containing different concentration MPP⁺ for 12 h. The 3 (4,5-dimethylthiazol)-2-yl-2,5-diphenyltetrazolium bromide (MTT) solution (1 mg/ml MTT in phosphate-buffered saline) was added to each well for 12 h. The (4,5-dimethylthiazol)-2-yl-2,5-diphenyltetrazolium formed formazan crystals. Optical absorbance was calculated using ImageJ.

### Immunoprecipitation

Briefly, microglia or BV2 cells were harvested and extracted in the lysis buffer containing 2 mM EDTA or 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 1% NP40, and 2 mM EDTA. The antibody DICER (4 μg) was added into the lysates, and the mixtures were rotated at 4 °C overnight. Protein A/G beads were then added into the mixtures which were incubated for 2 h at room temperature. After washing three times with the lysis buffer, the immunoprecipitated proteins were analyzed using Western blotting.

### Enzyme-linked immunosorbent assay of TNF-α

The TNF-α levels in the medium of microglia after LPS and/or MPP⁺ were assessed by ELISA using a mouse TNF-α ELISA kit (BD Biosciences) according to the manufacturer’s instructions.

### Immunohistofluorescence and image analysis

The mice were perfused with saline followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (PB) 7 days after saline or MPTP injection. The isolated brains were postfixed in 4% paraformaldehyde for 7 days and then dehydrated in 30% (v/v) methanol. The tissue was then embedded in paraffin and 5 μm slices were cut. The slices were dewaxed in xylene, rehydrated in an alcohol series, and then immersed in 3% (v/v) H₂O₂ for 30 min. After three washes with PBS, the sections were incubated with the primary antibodies (GFAP (1:500), Iba1 (1:1000), TH (1:1000)) overnight at 4 °C. The membranes were washed and then incubated with the secondary polyclonal antibodies conjugated with horseradish peroxidase at room temperature for 2 h. The protein bands were visualized with an ECL Western blotting substrate kit, and their densities were then quantified by densitometry analysis using ImageJ.

### DICER phosphorylation analysis by mass spectrometry

The phosphorylation of DICER was assayed by mass spectrometry as reported previously [21]. Briefly, immunoprecipitated samples from microglia and BV2 cells by the antibody against DICER or IgG were prepared. The precipitated proteins were separated by SDS/7% PAGE gels and then transferred onto polyvinylidene difluoride (PVDF) membranes. After blocked with a normal donkey serum for 1 h and then incubated with the primary antibodies (GFAP (1:1000), Iba1 (1:1000), TH (1:1000)) overnight at 4 °C. After addition of the secondary antibodies, the sections were incubated for 2 h at room temperature followed by three washes with PBS. Images were obtained using Nikon Ti microscope (Nikon, Japan). TH counts by Image Pro Plus was performed through unbiased stereology and the fluorescence intensity of GFAP and Iba1 quantified by ImageJ was defined as the average intensity of glial scar area in MPTP-injected mice or the SNpc area in saline-injected mice.
peptides were acidified with 5% formic acid and separated on a C18 column, and peptides were analyzed by Thermo Q Exactive HF Mass Spectrometer.

**Plasmid construction**

The full-length sequences of mouse DICER from pCA-GEN (Addgene, Plasmid #50558) were subcloned into the pCIG vector. A hemagglutinin (HA) epitope sequence (YPYDVPDYA) was fused to the amino terminus of DICER, and the plasmid sequences were confirmed by sequencing analysis.

**Antibodies and drugs**

The following antibodies were used: TH (AB152) and spectrin (#Mab 1622) from Millipore; Iba1 (#01919741) from Wako; HA (H6908) and GFAP (G3893) from Sigma; Ago2 (sc-32877), Drosha (sc-33778), DICER (sc-30226), ubiquitin (sc-8017), phosphorylated JNK (sc-6254), and JNK (sc-7345) from Santa Cruz Biotechnology; Caspase-3 (9662), cleaved Caspase-3 (#9664 L), ERK1/2 (9102), phosphorylated ERK (9101S), phosphorylated p38 (9216S), and p38 (8690S) from Cell Signaling Technology; phospho Serine (37430) from Qiagen; CD11b-Alexa Fluor 488 (557672) and CD45-APC (559864) from BD Biosciences; Calpain-L-leucyl-norvalinal (MG115, C6706), and lactacystin (C8999) or MDL28170 (M6690), calpeptin (C8999) or MDL28170 (M6690), N-carbobenzoxy-1-leucyl-1-leucyl-norvalinal (MG115, C6706), and lactacystin (L6785) from Sigma; U0126 (HY-12031), SP600125 (S7312) from Selleck.

**Statistics**

Data were mean ± SEM. All experiments were done independently at least three times. All statistical analyses were conducted using Office Excel 2007 and GraphPad Prism 5. Two-tailed Student’s t tests were used for comparisons between two groups and one-way ANOVA with Newman-Keuls post hoc test for more than two groups. Differences were considered to be significant when a p value is less than 0.05.

**Results**

**Microrn DICER protein is specifically downregulated in the mouse MPTP model**

We first examined whether DICER expression is affected in microglia, neurons, or astrocytes in the mouse MPTP model. Exposure of the primary cultured microglia to MPP+ led to a great reduction in DICER protein levels (Fig. 1a). In contrast, the levels of other proteins important for microRNA processing, including Argonaute 2 (Ago2), the core component of RNA-induced silencing complex (RISC), and Drosha, a nuclear RNase III, remained unchanged in microglia treated with MPP+ (Fig. 1b). Further, DICER expression was not affected in the primary cultured mouse neurons or astrocytes in response to various concentrations of MPP+ (Fig. 1c). Moreover, there was no difference in microglia viability in the absence or presence of MPP+ for 12 h as assayed by the MTT test (Additional file 1a). These results provided the initial evidence to suggest that DICER expression is specifically suppressed in microglia by MPP+.

We then examined the effects of MPP+ on DICER expression in the BV2 cells, a murine microglial cell line that is commonly used for investigation of microglia function [22]. Similarly, decreased expression of DICER by MPP+ was evident, whereas that of Ago2 or Drosha was not observed (Fig. 1d). The MTT test showed that MPP+ did not affect the viability of BV2 cells (Additional file 1b). We then examined microglial DICER levels in the mouse MPTP model. We sorted microglia by fluorescence-activated cell sorting (FACS) and studied DICER expression in the microglia. We found that DICER expression was greatly suppressed in the cluster of differentiation molecule 11B (CD11b)-positive and CD45-low microglia in ventral mesencephalon (VM) of mice 3 days after MPTP injection. In contrast, the expression of Ago2 and Drosha was not changed (Fig. 1e). To clarify whether DICER expression in astrocytes is changed, we isolated glutamate aspartate transporter (GLAST, the astrocyte marker)-positive cells by FACS and found that there was no difference in DICER levels between saline- and MPTP-injected mice (Fig. 1f). Altogether, these results suggest that DICER proteins in microglia are specifically downregulated in the mouse MPTP model.

**Proteasome mediates microglial DICER downregulation induced by MPP+**

We next investigated whether the reduction in DICER protein level is due to its mRNA reduction. We measured DICER mRNA levels by quantitative real-time PCR (qRT-PCR) and observed that DICER mRNA levels were not changed in microglia (Fig. 2a) and BV2 cells (Fig. 2b) following MPP+ engagement. Similarly, DICER mRNA levels in FACS-isolated microglia from mice injected with MPTP were not changed compared with those from mice injected with saline (Fig. 2c). These results suggest that the reduction in DICER protein levels might be attributed to post-translational regulation. It has been reported that DICER can be degraded by proteases (calpain-1 and caspase-3) [23–25] or proteasome [26, 27]. We explored whether DICER reduction is due to either proteases or proteasome. As illustrated in Fig. 2d and Additional file 2a, the cleaved fragment of α-spectrin, one of the well-defined calpain substrates [28], was not observed in microglia or BV2 cells incubated with MPP+ for different times, suggesting that calpain is not activated, and hence, it is
Fig. 1 (See legend on next page.)
unlikely that calpain is involved in DICER reduction caused by MPP⁺. This notion was further supported by the findings that DICER reduction was not rescued by calpeptin or MDL28170, the calpain inhibitors (Fig. 2e and Additional file 2d), although they greatly inhibited glutamate-induced the cleavage of α-spectrin into the characteristic fragments in neurons (Additional file 2b). Additionally, caspase-3 activation was not observed in microglia incubated with MPP⁺ (Fig. 2f and Additional file 2c). Moreover, the addition of Z-DEVD-FMK (DEVD), an agent known to inhibit caspase-3, to the microglia did not affect MPP⁺-induced DICER reduction (Fig. 2g). However, MPP⁺-induced DICER reduction was markedly prevented when the microglia were incubated with lactacystin or N-carbobenzoxyl-L-leucyl-L-leucyl-norvalinal (MG115), agents known as proteasome inhibitors (Fig. 2h, i and Additional file 2e, f). These results suggest that proteasome participates in MPP⁺-induced DICER degradation. This assumption was further supported by the findings that DICER ubiquitination was greatly increased when microglia were incubated with MPP⁺ (Fig. 2j) and Additional file 2g). Taken together, these observations suggest that MPP⁺-induced DICER reduction in microglia is due to its degradation mediated by proteasome.

**JNK is microglial DICER degradation induced by MPP⁺**

It has been reported that phosphorylation of a protein plays a role in its proteasomal degradation [29]. Treatment of microglia with MPP⁺ greatly increased the activities of mitogen-activated protein (MAP) kinases, including the extracellular signal-regulated kinases (ERKs, p42, and p44), the c-Jun N-terminal kinases (JNKs), and the p38 MAP kinases as evidenced by their respective phosphorylations. The ERK, JNK, and p38 MAPK were activated as early as 5 min after MPP⁺ engagement both in microglia (Fig. 3a–c) and BV2 cells (Fig. 3d–f). To assess the role of MAPKs in MPP⁺-induced DICER degradation, we then examined the effects of inhibition of these kinases on DICER degradation. Incubating microglia with U0126, SP600125, or SB203580, agents known as specific inhibitors to ERK, JNK, or p38 MAP kinase, respectively, markedly suppressed the phosphorylation of these kinases (Additional file 3a–c). The MPP⁺-induced DICER degradation was reversed when the microglia (Fig. 3h) or BV2 cells (Fig. 3j) were incubated with SP600125. In contrast, U0126 and SB203580 did not affect MPP⁺-induced DICER degradation (Fig. 3g–j). In addition, SP600125 eliminated MPP⁺-induced DICER ubiquitination (Fig. 3k). Together, these results provided the initial evidence to suggest that JNK might participate in MPP⁺-induced DICER degradation.

**Serine 1456 in microglial DICER is phosphorylated by JNK**

We next examined whether JNK has a role in DICER phosphorylation and degradation. We transfected HEK293 cells with JNK and hemagglutinin (HA) epitope-tagged DICER expression constructs and immunoprecipitated whole cell lysates with HA antibody followed by immunoblotting using the antibody against phosphorylated serine. As shown in Fig. 4a, a phosphoserine signal at DICER position was detected, whereas no signal was observed without JNK transfection, suggesting that serine phosphorylation of DICER is JNK-dependent. Exposure of microglia to MPP⁺ caused an increase in phosphorylated serine signal migrating at DICER position (Fig. 4b). Similarly, elevation of serine phosphorylation of DICER was found in BV2 cells by MPP⁺ (Fig. 4c). Moreover, MPP⁺-induced serine phosphorylation of DICER was suppressed by SP600125 (Fig. 4d). Taken together, these results suggest that MPP⁺ activates JNK to phosphorylate DICER.

To clearly show that DICER is indeed phosphorylated by JNK, we used liquid chromatography-tandem mass spectrometry to further identify the phosphorylation site(s) of DICER in microglia exposed to MPP⁺. Mass spectrometry (MS) analysis of the DICER from MPP⁺-treated microglia (Fig. 4e) and BV2 cells (Additional file 4a) revealed that mouse DICER contained a phosphorylation site for DICER. The bioinformatics
Fig. 2. Inhibition of proteasome suppresses microglial DICER downregulation induced by MPP⁺. 

(a, b) Quantitative PCR analysis of DICER mRNA levels in microglia (a, n = 4) and BV2 cells (b, n = 4) treated with MPP⁺ (100 μM) for 12 h. 

(c) Quantitative PCR examination of DICER mRNA levels in microglia sorted from VM of mice after saline or MPTP injection (n = 4). 

d) Representative immunoblots of total lysates from microglia treated with MPP⁺ for the indicated times with the antibody against α-spectrin. 

e) Representative immunoblots of total lysates from BV2 cells incubated with MPP⁺ together with the calpeptin (CAL, 10 μM) or MDL28170 (MDL, 60 μM) for 12 h and probed with the indicated antibodies. 

f) Representative immunoblots of total lysates from microglia treated with MPP⁺ for the indicated times using the antibodies against caspase-3 or cleaved caspase-3. 

g) Left—representative immunoblots of total lysates from BV2 cells incubated MPP⁺ with/without Ac-DEVD-CHO (DEVD, 10 μM) and probed with the indicated antibodies. 

Right—statistics (n = 4). 

h, i) Upper—representative immunoblots of total lysates from microglia treated with MPP⁺ with/without lactacystin (LAC, 1 μM, h) or N-carbobenzoxy-l-leucyl-l-leucyl-norvalinal (MG115, 1 μM, i) for 12 h and probed with the indicated antibodies. Lower—statistics (n = 3 for LAC and n = 4 for MG115). 

j) Representative immunoblots of immunoprecipitates of total lysates from microglia treated with/without MPP⁺ in the presence of MG115 and then probed with anti-ubiquitin antibody. Unless stated, 100 μM MPP⁺ was used. The corresponding mRNA levels were normalized to actin levels. Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 3 Inhibition of JNK suppresses microglial DICER degradation induced by MPP⁺.

a-f Representative immunoblots of total lysates from microglia (a–c) and BV2 cells (d–f) exposed to MPP⁺ for the indicated times and probed with the antibodies for p-ERK and ERK (a, d), for p-JNK and JNK (b, e), and for p-p38 and p38 (c, f).

g–j Representative immunoblots of total lysates from microglia (g–i) and BV2 cells (j) treated with MPP⁺ or/and U0126 (g, j, 10 μM), SP600125 (SP, 10 μM) (h, j), and SB203580 (SB, 10 μM) (i, j) using the antibodies against DICER. Lower—statistics (g–i; n = 3 for g, n = 4 for h, and n = 3 for i and n = 3 for j).

k Upper—representative immunoblots of immunoprecipitates from total lysates of BV2 cells pretreated SP600125 for 2 h and then incubated with MG115 with/without MPP⁺ and immunoblotted with anti-ubiquitin antibody. Lower—immunoblots of the DICER precipitates. Data are mean ± SEM. *p < 0.05.
prediction using Group-based Prediction software 3.0, a tool used to predict of kinase-specific phosphorylation sites [30], suggested that serine 1456 is a new candidate JNK phosphorylation site (Additional file 4b). Sequence analysis revealed that the Ser 1456 is followed by a proline, consistent with the notion that DICER is phosphorylated by JNK, a well-known proline-directed kinase. The MS analysis further revealed that MPP+ induced Ser 1456 phosphorylation, and the phosphorylation was abolished by SP600125 in microglia (Additional file 4c). Altogether, these results suggest that JNK indeed mediates DICER serine 1456 phosphorylation.

Inhibiting DICER Ser 1456 phosphorylation prevents the MPP+-induced DICER degradation

To provide clear evidence that Ser 1456 phosphorylation is indeed important for MPP+-induced DICER degradation, we designed a synthetic peptide comprising amino acid sequence 1448–1465 spanning the JNK phosphorylation site of mouse DICER, fused it to the protein transduction domain of the HIV-1 transactivator protein (TAT) and named it as TAT-DICER (Fig. 5a). Initial experiments were performed to investigate if the TAT-DICER could indeed affect Ser 1456 phosphorylation of DICER. As shown in Fig. 5b, TAT-DICER did inhibit Ser 1456 phosphorylation.
phosphorylation in microglia induced by MPP⁺. Moreover, the TAT-DICER also suppressed DICER degradation in microglia induced by MPP⁺ (Fig. 5c). Similar results were also obtained in BV2 cells (Fig. 5d). Consistently, TAT-DICER greatly inhibited MPP⁺-induced DICER ubiquitination (Fig. 5e). Collectively, these results suggest that JNK-mediated Ser 1456 phosphorylation plays a crucial role in DICER degradation.

**Microglial DICER degradation by MPP⁺ potentiates its inflammatory responses**

Since microglia is the central immunocompetent cells in the brain [31], we investigated whether DICER degradation plays a role in microglial inflammatory responses. We evaluated the microglial activation by measuring the expression of pro-inflammatory mediators, including TNF-α, interleukin 1 beta (IL-1β), inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) (Fig. 6a). The qRT-PCR analysis showed that mRNA levels of these factors were not affected by MPP⁺, suggesting that MPP⁺-regulated DICER degradation does not initiate the microglial inflammatory responses (Fig. 6b–e). Nevertheless, when microglial cells were incubated with lipopolysaccharide (LPS), an agent well known to activate microglia, the expression of these factors was increased (Fig. 6b–e). Moreover, the increased expression of these factors was greatly amplified when the microglia were pre-exposed to MPP⁺ (Fig. 6b–e). In addition, TNF-α protein level measured by enzyme-linked immunosorbent assay (ELISA) was also markedly potentiated (Fig. 6f). These results point to a possibility that DICER degradation caused by MPP⁺ leads to the hyper-microglial inflammatory responses.
To directly explore whether the reduction in DICER indeed has a role in microglial responses to LPS, we examined the effects of TAT-DICER on the production of these factors induced by LPS in the presence or absence of MPP+. The TAT-DICER did not affect the production of TNF-α, IL-1β, iNOS, and COX-2 induced by LPS (Fig. 6g–j). In contrast, the production of these factors potentiated by MPP+ was eliminated when microglia were incubated with TAT-DICER, but not with TAT-scramble (Fig. 6g–j). Additionally, exposure to TAT-DICER, but not to TAT-scramble, abolished MPP+-potentiated TNF-α protein production (Fig. 6k). Thus, DICER reduction
induced by MPP\(^+\) greatly contributes to the amplification in microglial inflammatory responses.

**Inhibiting microglial DICER degradation limits its hyper-inflammatory responses and rescues TH-positive neuron loss in the mouse MPTP model**

The results above suggest that DICER in microglia is degraded in the MPTP models and that its degradation leads to the exaggerated inflammatory responses in cultured microglia. To show whether DICER degradation has a role in the regulation of microglial inflammatory responses in the mouse MPTP model, we injected TAT-DICER or TAT-scramble into the mice and examined their effects on DICER reduction and inflammation. Western blot analysis of the total lysates of the microglia isolated by FACS from the ventral mesencephalon revealed that the TAT-DICER remarkably inhibited DICER degradation in the mice injected with MPTP (Fig. 7a).

Next, we detected microglial or astrocytic activation as evidenced by ionized calcium-binding adapter molecule 1 (Iba1) or glial fibrillary acidic protein (GFAP) immunohistofluorescence staining, respectively. Neither TAT-scramble nor TAT-DICER itself affected Iba1 and GFAP expression. In contrast, the expression of Iba1 and GFAP was increased in mice injected with MPTP, and the increased expression of Iba1 and GFAP was markedly inhibited by TAT-DICER, but not by TAT-scramble (Fig. 7b, d).

To determine whether TAT-DICER-inhibited glial activation has a role in nigral dopaminergic neuron loss in the mouse MPTP model, we counted tyrosine hydroxylase (TH, a marker for dopamine neurons)-positive neuron number in the mice. The numbers of TH-positive neurons were greatly reduced in the mouse MPTP model and TAT-DICER markedly prevented the reduction in the number of TH-positive neurons caused by MPTP (Fig. 7c, d). Taken together, these results suggest that microglial DICER degradation in the mouse MPTP model greatly contributes to glial hyperactivation and TH-positive neuron loss.

**Discussion**

In this study, we report JNK-mediated degradation of DICER by neurotoxin MPP\(^+\) and its crucial role in microglial hyper-inflammatory responses to cause dopamine (DA) neuron loss. Several lines of experimental results support this conclusion. First, microglial DICER was specifically degraded by the proteasomal pathway in response to MPP\(^+\). Second, MPP\(^+\) caused JNK activation and inhibition of JNK activities stopped microglial DICER degradation. Third, JNK phosphorylated DICER at serine 1456. Fourth, inhibition of microglial DICER Ser 1456 phosphorylation prevented its degradation as well as its hyper-inflammatory responses. Last, inhibition of microglial DICER degradation limited its hyperactivation and reduced DA neuron loss in the mouse MPTP model. Since specific and progressive dopaminergic neuron loss is one of the key characteristics of the PD pathology, the microglial DICER degradation suggests a particular role of this specific regulation of DICER in the pathogenesis of PD. Thus, preventing microglial DICER degradation may be a new strategy to curb microglial hyper-inflammatory responses and DA neuron loss in PD (Fig. 7e).

The DICER has important roles in diverse biological processes, including chromatin structure remodeling, immune responses, and stem-cell maintenance and differentiation [32–35]. Therefore, DICER expression level should be tightly controlled. At the post-translational level, DICER is glycosylated to maintain its intracellular level and proper folding [36]. Smoking-induced DICER SUMOylation in lung macrophages results in abnormal profiles of microRNA expression [37]. Phosphorylation of DICER on Ser 1705 and Ser 1833 by ERK triggers its nuclear localization to coordinate oocyte-to-embryo transition in the development of Caenorhabditis elegans [38]. Here, we showed that JNK phosphorylation of microglial DICER at Ser 1456 induced by neurotoxin MPP\(^+\) promotes its degradation. Injection of TAT-DICER, a cell-permeable peptide with the ability to pass the blood-brain barrier [39–41], prevented DICER phosphorylation and degradation. Thus, DICER is phosphorylated by different kinases to function in different biological processes. It should be pointed out that although JNK activation is found in neurons, astrocytes [42, 43], and microglia, DICER degradation induced by MPP\(^+\) was observed only in microglia. It is thus possible that an E3 ligase specific for DICER is present only in microglia. This assumption is consistent with the findings that inhibition of DICER phosphorylation by TAT-DICER suppressed its ubiquitination and degradation in microglia induced by MPP\(^+\).

Previous studies reported that a genetic deletion of DICER in forebrain excitatory neurons or oligodendrocytes leads to astrogliosis and microgliosis [17, 44], while little is known about the role of DICER in microglia. One important finding of the current study is that microglial DICER degradation potentiated its inflammatory responses. A recent study showed that DICER knock-out in adult microglia leads to hyperactivation of these cells after LPS challenges [45]. Therefore, it is likely that DICER can affect the inflammation in cell autonomous and non-cell autonomous manners. In this context, inhibiting DICER reduction to curb inflammation is a novel approach to specifically affect the inflammatory process. It remains unclear how DICER affects microglial inflammatory responses. Our recent work reports that miR-7116-5p, a microRNA targeting TNF-α, is downregulated by MPP\(^+\) and potentiates TNF-α production in microglia [9]. Therefore, changes in
Fig. 7 Inhibition of microglial DICER degradation suppresses inflammatory responses and reduces tyrosine hydroxylase-positive neuron loss in the mouse MPTP model. a Left—representative immunoblots of total lysates of microglia sorted from VM of mice 3 days after saline or MPTP injection together with TAT-Scr. or TAT-DICER and probed with the antibody against DICER. Right—statistics (n = 5). b, c Representative images of immunohistofluorescence staining with antibodies against Iba1 (top two, b) and GFAP (bottom two, b) in the ventral tegmental area and tyrosine hydroxylase (c) in the SNpc of mice 7 days after the administration of saline or MPTP with TAT-Scr. or TAT-DICER. In b, the images in the small squares magnified from the area indicated by the red arrows. Scale bar, 200 μM. AOD, average optical densities. d Statistics for b (top two, n = 6 for Iba1 and n = 5 for GFAP) and c (bottom, n = 4). e Schematic diagram of the working model. Microglial DICER phosphorylation and degradation by MPP* amplified the inflammation caused by damaged neurons, leading to enhanced DA neuron loss. Data are mean ± SEM. *p < 0.05, **p < 0.001, ##p < 0.01.
microRNA expression likely play an important role in DICER deficit-induced inflammation. Additionally, DICER deficit in the retinal pigmented epithelium induces accumulation of Alu RNA to activate NLRP3 inflammasome [18, 46]. It is not clear whether microglial hyperactivation responses induced by DICER degradation are due to the long non-coding RNA Alu-dependent mechanism.

From the lessons of the current clinical trials of Alzheimer’s disease [47], it is believed that there is no beneficial effect to inhibit inflammation in late-stage patients who have been with obvious symptoms, and it is therefore necessary to select a right time to curb the amplified inflammation. A key finding of the current study is that DICER is degraded at the early time in the pathogenic process in the mouse MPTP model. Consistently, preventing DICER degradation at this stage significantly suppressed glial activation and improved DA neuron survival. Additionally, pre-treating mice with eicosanoyl-5-hydroxysterigmatane, which had a direct anti-inflammatory effect, for 4 weeks showed a robust protection for dopaminergic neurons following MPTP challenge [48], and co-administration anti-inflammatory drug MDG548 injected 15 min before MPTP prevented DA neuron loss [49]. Moreover, the use of ibuprofen, a compound known to inhibit inflammation, is associated with lowering PD risk [50]. Therefore, the inhibition of inflammation by the early inhibition of DICER degradation would be a promising strategy to prevent neurodegeneration.

Conclusions
Microglial DICER is phosphorylated by JNK to induce its degradation, potentiate microglial inflammatory processes, and enhance DA neuron damage. These observations revealed an unknown regulatory mechanism of microglial DICER and its role in promoting microglial hyperactivation of inflammation in the mouse MPTP model. The demonstration of JNK-mediated DICER degradation in the brain will further expand our understanding of the amplification of microglial inflammation.

Additional files

Additional file 1: Related to Fig. 1 (a and b) The viability of microglia (a, n = 3) and BV2 cells (b, n = 3) determined by MTT assay 12 h after MPP+ treatment. Data shown as mean ± SEM. (PNG 17 kb)

Additional file 2: Related to Fig. 2 (a) Representative immunoblots of total lysates of BV2 cells treated with 100 μM MPP+ for the indicated times with the antibody against α-spectrin. (b) Representative immunoblots of total lysates of primary cultured neurons treated with 50 μM glutamate (Glu) or/and calpeptin (CAL) or MDL28170 (MDL) for 4 h with the antibody against α-tubulin. (c) Representative immunoblots of total lysates of primary cultured neurons treated with 50 μM glutamate (Glu) or/and calpeptin (CAL) or MDL28170 (MDL) for 4 h with the antibody against α-spectrin. (d) Representative immunoblots of total lysates of BV2 cells treated with MPP+ for the indicated times with the antibody against caspase-3 and cleaved caspase-3. (e) Statistics of DICER in Fig. 2e. (f) Upper, representative immunoblots of total lysates from BV2 cells treated with U0126 (a), SP (b), and SB (c) with indicated antibodies; α-tubulin (α-Tub), a loading control. kDa, kilodalton. (PNG 512 kb)

Additional file 3: Related to Fig. 3 (a–c) Representative immunoblots of total lysates of BV2 cells treated with U0126 (a), SP (b), and SB (c) with indicated antibodies; α-tubulin (α-Tub), a loading control. kDa, kilodalton. (PNG 54 kb)

Additional file 4: Related to Fig. 4 (a) Mass spectrometry (MS) analysis of the DICER immunoprecipitated from BV2 cells treated with MPP+ for 30 min. The phosphorylated serine residue as revealed by MS is shown in lowercase bold letter. (b) Table representing a list of JNK phosphorylation sites of DICER predicted by GPS3.0. (c) MS analysis of the DICER immunoprecipitated from microglia pre-incubated with or without SP for 2 h and then with MPP+ for 30 min. The phosphorylated serine residue as revealed by MS is shown in lowercase bold letter. (PNG 289 kb)

Abbreviations
Ago2: Argonaute 2; APC: Allophycocyanin; CD11b: Crossing cluster of differentiation molecule 11B; CD45: Cluster of differentiation 45; COX-2: Cyclooxygenase-2; DEVD: Z-DEVD-FMK; ELISA: Enzyme-linked immunosorbent assay; ERK: Extracellular signal-regulated kinase; FACS: Fluorescence-activated cell sorter; FBS: Fetal bovine serum; GFAP: Glial fibrillary acidic protein; GLAST: Glutamate aspartate transporter; Ibal1: Ionized calcium-binding adaptor molecule 1; IL-1β: Interleukin-1 beta; iNOS: Inducible nitric oxide synthase; JNK: c-jun N-terminal kinase; LPS: Lipopolysaccharide; MAP: Mitogen-activated protein; MG115: N-carbobenoxyl-L-leucyl-L-leucyl-ornivalinal; MPP+: 1-Methyl-4-phenylpyridinium; MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MS: Mass spectrometry; MTT: 3 4,5-Dimethylthiazol-2-yl-2,5-diphenyl-tetrazolium bromide; PBS: Phosphate-buffered saline; PD: Parkinson’s disease; PFA: Paraformaldehyde; PVDF: Polyvinylidene difluoride; qRT-PCR: Quantitative real-time PCR; SNC: Substantia nigra compacta; TH: Tyrosine hydroxylase; TNF-α: Tumor necrosis factor-alpha; VM: Ventral mesencephalon

Acknowledgements
The authors thank L. Wu and X. Li for the cell cultures and MF. Liu, RG. Hu, ZG. Luo, and JW. Zhou for the discussion.

Funding
The work is supported by grants from the Ministry of Science and Technology of China (2015ZX09102005) and Beijing Municipal Science and Technology Commission (Z151100003915120).

Availability of data and materials
All data supporting the conclusions of this study are presented in the manuscript.

Authors’ contributions
GQ, QH, and YFC performed the experiments and wrote the manuscript. WS corrected the manuscript. CY did the imaging. YZW supervised the study and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval
All animal studies were performed with the approval by the Institutional Animal Care and Use Committee of the Institute of Neuroscience, Shanghai, China.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Dicer ablation in
brain pathology related to spastic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.

2. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson’s disease. Exp Mol Med. 2006;38:333–47.

3. Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(S2):20–2.

4. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 2003;304:1–7.

5. Long-Smith CM, Sullivan AW, Nolan YM. The influence of microglia on the pathogenesis of Parkinson’s disease. Prog Neurobiol. 2009;89:277–87.

6. Dutta G, Zhang P, Liu B. The Iipooyosacharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fund Clin Pharmacol. 2008;22:453–64.

7. Gao HW, Liu B, Zhang WQ, Hong JS. Novel anti-inflammatory therapy for Parkinson’s disease. Trends Pharmacol Sci. 2003;24:395–401.

8. Qin L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm. 2010;117:971–9.

9. He Q, Wang Q, Yuan C, Wang Y. Downregulation of miR-716-5p in microglia by MPP4(-) sensitizes TNF-alpha production to induce dopaminergic neuron damage. Glia. 2017;65:1251–63.

10. Wichmann T, Delong MR. Pathophysiology of Parkinson’s disease: the MPTP primate model of the human disorder. Parkinson’s Disease. The Life Cycle of the Dopamine Neuron. 2003;991:199–213.

11. Smeeny RJ, Jackson-Lewis V. The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res. 2005;134:57–66.

12. Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318:215–24.

13. Ponomarev ED, Verenevyts T, Barteniev N, Kirichevyk AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med. 2011;17:649–54.

14. Yang Z, Zhong L, Xian R, Yuan B. MicroRNA-223 regulates inflammation and macrophages via the C/EBPalpha-PU.1 pathway. Nat Med. 2011;17:64–5.

15. Gross TJ, Powers LS, Boudreau LR, Blink B, Reisetter A, Goel G, Gerke AK, Hassan IH, Monick MM. A microRNA processing defect in smokers’ macrophages is linked to SUMOylation of the endonuclease DICER. J Biol Chem. 2014;289:12823–34.

16. Yamasaki Y, Irimura T, Suematsu K, Yokomizo Y, Tanaka K, Aida Y, et al. Aberrant expression of microRNA-223 in focal cerebral ischemia. Stroke. 2015;46:1341–8.

17. Varol D, Mildner A, Blank T, Shemer A, Barashi N, Yona S, David E, Boura-Hallon S, Segal-Hayoun Y, Chappell-Maor L, et al. Dicer deficiency conversion of Dicer ribonucleo into a death-promoting deoxyribonucleos. Science. 2010;328:327–34.

18. Casey Klockow L, Shariﬁ HT, Wu X, Flagg M, Furuya AK, Nekorchuk M, de Noronha CM. The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection. Virology. 2013;444:191–202.

19. Zhang Z, Convertini P, Shen M, Xu X, Leimeoni F, de la Grange P, Andres DA, Stamm S. Valproic acid causes proteasomal degradation of Dicer and influences miRNA expression. PLoS One. 2013;8(6):e62895.

20. Neumar RW, Xu YA, Gada H, Guttmann RP, Simon R. Cross-talk between calpain and caspase proteolytic systems during neuronal apoptosis. J Biol Chem. 2003;278:14162–7.

21. Hunter T. The age of crossstalk: phosphorylation, ubiquitination, and beyond. Mol Cell. 2007;28:730–8.

22. Xue Y, Ren J, Gao X, Jin C, Wen L, Yao X. GPS 2.0, a tool to predict kinase-specific phosphorylation sites in hierarchy. Mol Cell Proteomics. 2008;7:1598–608.

23. Cross AK, Woodroofe MN. Immunoregulation of microglial functional properties. Microsc Res Tech. 2001;54:10–7.

24. Devathanam AS, Tomasi TB. Dicer in immune cell development and function. Immunol Invest. 2014;43:182–95.

25. Kanellopoulou C, Muljo SA, Kung AL, Drapkin R, Jensen T, Livingston DM, Rajewsky K. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing Genes Dev. 2005;19:849–501.

26. Bouck N, Kim SY, Carmell MA, Murchison EP, Acolin H, Li MZ, Mills A, Elledge SJ, Anderson KV, Hannon GJ. Dicer is essential for mouse development. Nat Genet. 2003;33:287.

27. Klaae Z, Kale P, Winograd R, Gupta MV, Heydarian M, Bero R, McCallie T, Kashchanski F. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chemotod modeling of the viral LTR. BMC Biol. 2007;5:66.

28. Pippin G, Pieroni MP, Provot P. Regulation of human Dicer by the resident ER membrane protein CLIMP-63. Nuclear Acids Res. 2012;40:11603–17.

29. Gross TJ, Powers LS, Boudreau L, Blink B, Reisetter A, Goel G, Gerke AK, Hassan IH, Monick MM. A microRNA processing defect in smokers’ macrophages is linked to SUMOylation of the endonuclease Dicer. J Biol Chem. 2014;269:12823–4.

30. Eknal M, Furtas T, Sun KM, Gonzalez G, Liu B, Kalia A, Ladbury JE, Fire AZ, Skaeth JB, Anur S. A requirement for ER-dependent Dicer phosphorylation in coordinating oocyte-to-embryo transition in C. elegans. Dev Cell. 2014;31:614–28.

31. Wang J, Lu R, Yang Q, Li H, He Z, Jing N, Wang X, Wang Y. TRPC6 specifically interacts with APP to inhibit its cleavage by gamma-secretase and reduce Aβeta production. Nat Commun. 2015;6:6887.

32. Bellone C, Luscher C. Cacaine triggered AMPA receptor redistribution is reversed in vivo by miL1-dependent long-term depression. Nat Neurosci. 2006;9:636–41.

33. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavanayee S, Pant HC. A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer’s disease phenotypes in model mice. FASEB J. 2013;27:174–86.

34. Saporito MS, Thomas BA, Scott RW. MPTP activates c-Jun NH2-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem. 2000;75:1200–07.

35. Shin D, Shin JY, McManus MT, Ptacek LJ, Fu YH. Dicer ablation in oligodendrocytes provokes neuronal impairment in mice. Ann Neurol. 2009;66:54–73.

36. Tarallo V, Hirano Y, Gelfand BD, Dridi S, Kerur N, Kim Y, Cho WY, Kanoeki H, Fowler BJ, Bogdanovich S, et al. DICER1 loss and Au RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell. 2012;149:847–59.

37. Shao W, Zhang SZ, Tang M, Zhang XH, Zhou Z, Yin YQ, Zhou QB, Huang YY, Liu YJ, Wawrousek E, et al. Suppression of neuroinflammation by astrocytic dopamine D2 receptors via alpha B-crystallin. Nature. 2013;494:90–4.

38. Tai Y, Feng S, Ge R, Du W, Zhang X, He Z, Wang Y. TRPC6 channels promote dendritic growth via the CaMKIV-CREB pathway. J Cell Sci. 2008;121:2901–7.

39. Ding C, Chan DW, Liu W, Lu M, Li D, Song L, Li C, Jin J, Makaravanan A, Jurk SY, et al. Proteome-wide profiling of activated transcription factors with a concatenated tandem array of transcription factor response elements. Proc Natl Acad Sci U S A. 2013;110:6771–6.

40. Blasi E, Barluzzi R, Bocchini V, Mazzolla R, Bistoni F. Immortalization of murine microglial cells by a v-raf/v-myc carrying retrovirus. J Neuroimmunol. 1990;22:229–37.

41. Eghhezawy A, Shi L, Hu J, Wittig I, Laban H, Pircher J, Mann A, Provost P, Randriamaavoanjanv F, Fleming I. Dicer cleavage by calpain determines platelet microRNA levels and function in diabetes. Circ Res. 2015;117:157–65.

42. Lugli G, Larson J, Martone ME, Jones Y, Smalheiser NR. Dicer and eIF2c2 are enriched at postsynaptic densities in adult mouse brain and are modified by neuronal activity in a calpain-dependent manner. J Neurochem. 2005;94:896–905.

43. Nakagawa A, Shi Y, Kage-Nakai E, Mitani S, Xue D. Caspase-dependent conversion of Dicer ribonucleo into a death-promoting deoxyribonucleos. Science. 2010;328:327–34.
differentially impacts microglia of the developing and adult brain. Immunity. 2017;46:1030–44.
e 46. Kaneko H, Dridi S, Tarallo V, Gelfand BD, Fowler BJ, Cho WG, Kleinman ME, Ponicsan SL, Hauswirth WW, Chiodo VA, et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011;471:325–30.
47. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging. 2007;28:639–47.
48. Lee KW, Im JY, Woo JM, Grosso H, Kim YS, Cristovao AC, Sonsalla PK, Schuster DS, Jalbut IW, Fernandez JR, et al. Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson’s disease. Neurotherapeutics. 2013;10:143–53.
49. Lecca D, Nevin DK, Mulas G, Casu MA, Diana A, Rossi D, Sacchetti G, Carta AR. Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARgamma agonist in vitro and in MPTP-treated mice. Neuroscience. 2015;302:23–35.
50. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76:863–9.